Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 5/20 | 0.50 |
| ▸ | DRD3 | P35462 | 5/20 | 0.50 |
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17861418 | 0.84 | DRD2 (0.51) | DRD2FAAHDRD3CNR1SIGMAR1 | |
| SCHEMBL7067307 | 0.84 | DRD2 (0.60) | DRD2SLC6A4DRD3HRH3KDM4E | |
| SCHEMBL7662199 | 0.84 | DRD2 (0.54) | DRD2SIGMAR1JAK2JAK1 | |
| SCHEMBL14619656 | 0.83 | DRD2 (0.60) | DRD2DRD3SIGMAR1 | |
| SCHEMBL17865091 | 0.82 | DRD2 (0.72) | DRD2FAAHDRD3CNR1 | |
| SCHEMBL5705202 | 0.81 | DRD2 (0.54) | DRD2SIGMAR1CNR2JAK2JAK1 | |
| SCHEMBL6133832 | 0.80 | CCR2 (0.66) | — | |
| SCHEMBL12502091 | 0.79 | CCR1 (0.58) | DRD2FAAHDRD3CNR1SIGMAR1 | |
| SCHEMBL6200348 | 0.78 | ADRA1A (0.62) | DRD2DRD3SIGMAR1JAK2JAK1 | |
| SCHEMBL7957071 | 0.77 | DRD2 (0.54) | DRD2SLC6A4DRD3HRH3KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040242609-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | H. LUNDBECK A/S (DK) | 2003-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030082623-A1 | DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof | MCHR1, MCHR2, MC1R | DRD2 271/4885SLC6A4 207/4885FAAH 1934/4885 |
| US-20040242609-A1 | Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof | MCHR1, MCHR2, MC4R | DRD2 175/4885SLC6A4 527/4885FAAH 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.